Particle.news
Download on the App Store
5 ARTICLES
·
2mo ago

CDC Reports 80% Drop in Cervical Precancer Rates Among Vaccinated Young Women

Findings highlight the effectiveness of the HPV vaccine in reducing precancerous lesions in women aged 20-24 over a 14-year period.

FILE - A doctor holds a vial of the human papillomavirus (HPV) vaccine Gardasil in Chicago on Aug. 28, 2006. (AP Photo/Charles Rex Arbogast, File)
A certified medical assistant holds needles full of the HPV vaccination drug Gardasil before administering them to children at a health center in Texas. Photo: Matthew Busch for The Washington Post via Getty Images
Image
A schoolgirl receives a vaccine injection during a vaccination campaign against the papillomavirus (HPV infection) at the Jean Moulin Middle School in Le Bouscat, southwestern France

Overview

  • The CDC study found an approximately 80% reduction in cervical precancer rates among women aged 20-24 screened between 2008 and 2022, attributed to HPV vaccination efforts.
  • The HPV vaccine, first approved in 2006, is recommended for preteens aged 11-12, with catch-up doses for individuals up to age 26 who missed earlier vaccinations.
  • HPV is the most common sexually transmitted infection in the U.S. and is responsible for nearly all cases of cervical cancer, which affects around 10,800 women annually in the country.
  • While the study did not directly link vaccination status to outcomes, researchers noted no other plausible explanations for the significant decline in precancer rates.
  • Experts cite the findings as reassurance for parents about the vaccine's safety and effectiveness, with global vaccination programs aiming to eliminate cervical cancer within the next century.